Middleton & Co. Inc. MA Has $5.09 Million Stock Position in IDEXX Laboratories, Inc. (NASDAQ:IDXX)

Middleton & Co. Inc. MA increased its stake in IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 98.1% during the fourth quarter, Holdings Channel.com reports. The fund owned 12,305 shares of the company’s stock after buying an additional 6,095 shares during the period. Middleton & Co. Inc. MA’s holdings in IDEXX Laboratories were worth $5,087,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors also recently made changes to their positions in IDXX. FSA Wealth Management LLC acquired a new position in shares of IDEXX Laboratories in the third quarter worth approximately $25,000. Retirement Wealth Solutions LLC acquired a new position in IDEXX Laboratories in the fourth quarter valued at approximately $31,000. Ashton Thomas Securities LLC acquired a new position in IDEXX Laboratories in the third quarter valued at approximately $37,000. Kestra Investment Management LLC acquired a new position in IDEXX Laboratories in the fourth quarter valued at approximately $38,000. Finally, Crews Bank & Trust acquired a new position in IDEXX Laboratories in the fourth quarter valued at approximately $41,000. 87.84% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several research firms have recently commented on IDXX. Piper Sandler boosted their price objective on IDEXX Laboratories from $435.00 to $510.00 and gave the company a “neutral” rating in a report on Monday, February 10th. Leerink Partners assumed coverage on IDEXX Laboratories in a report on Monday, December 2nd. They set an “outperform” rating and a $500.00 price target for the company. StockNews.com upgraded IDEXX Laboratories from a “hold” rating to a “buy” rating in a report on Thursday. Barclays upped their price target on IDEXX Laboratories from $481.00 to $520.00 and gave the stock an “overweight” rating in a report on Tuesday, February 4th. Finally, Leerink Partnrs upgraded IDEXX Laboratories to a “strong-buy” rating in a research note on Monday, December 2nd. Three research analysts have rated the stock with a hold rating, seven have issued a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $533.75.

IDEXX Laboratories Stock Performance

Shares of IDXX opened at $437.11 on Friday. The stock’s 50-day simple moving average is $435.31 and its 200 day simple moving average is $451.54. The stock has a market capitalization of $35.55 billion, a price-to-earnings ratio of 40.97, a price-to-earnings-growth ratio of 3.41 and a beta of 1.37. The company has a debt-to-equity ratio of 0.28, a quick ratio of 0.95 and a current ratio of 1.31. IDEXX Laboratories, Inc. has a 52-week low of $398.50 and a 52-week high of $583.39.

Insider Buying and Selling

In related news, Director M Anne Szostak sold 3,000 shares of the stock in a transaction dated Friday, February 7th. The stock was sold at an average price of $465.94, for a total transaction of $1,397,820.00. Following the sale, the director now owns 3,061 shares of the company’s stock, valued at approximately $1,426,242.34. This represents a 49.50 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, EVP George Fennell sold 9,986 shares of the stock in a transaction dated Monday, February 10th. The stock was sold at an average price of $462.53, for a total value of $4,618,824.58. Following the sale, the executive vice president now directly owns 8,176 shares in the company, valued at $3,781,645.28. This trade represents a 54.98 % decrease in their position. The disclosure for this sale can be found here. 2.11% of the stock is currently owned by insiders.

About IDEXX Laboratories

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.